<?xml version="1.0" encoding="UTF-8"?>
<p>The inhibition of viral assemble is investigated for different types of viruses including moloney murine leukaemia virus (Mo‐MLV) (McNally, Wahlin, &amp; Canto‐Soler, 
 <xref rid="tbed13734-bib-0053" ref-type="ref">2010</xref>), classical swine fever virus (CSFV) (Zhou, Liu, &amp; Chen, 
 <xref rid="tbed13734-bib-0103" ref-type="ref">2008</xref>), HIV‐2 (Wu et al., 
 <xref rid="tbed13734-bib-0092" ref-type="ref">1995</xref>), HIV‐1 (Li et al., 
 <xref rid="tbed13734-bib-0043" ref-type="ref">2009</xref>), dengue virus type 2 (DENV2) (Qin et al., 
 <xref rid="tbed13734-bib-0060" ref-type="ref">2005</xref>), HBV (Seo et al., 
 <xref rid="tbed13734-bib-0068" ref-type="ref">2019</xref>) and influenza A (Liu et al., 
 <xref rid="tbed13734-bib-0045" ref-type="ref">2014</xref>). However, no approved drug candidate or in clinical trial disparting the SARS‐CoV‐2 assembly is reported so far.
</p>
